<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875784</url>
  </required_header>
  <id_info>
    <org_study_id>103629</org_study_id>
    <nct_id>NCT00875784</nct_id>
  </id_info>
  <brief_title>An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)</brief_title>
  <official_title>An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate) Injection 4mg Administered Using the IMITREX STATdose System® and a TREXIMA Tablet Followed by IMI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the exposure of sumatriptan after administration of TREXIMA&#xD;
      (sumatriptan 85mg/naproxen sodium 500mg) followed by a subcutaneous IMITREX injection (4mg or&#xD;
      6mg) 2 hours later compared to administration of a IMITREX 100mg tablet followed by a IMITREX&#xD;
      100mg tablet 2 hours later.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, 3-period crossover study to evaluate sumatriptan pharmacokinetics&#xD;
      for a TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX®&#xD;
      (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System® and a&#xD;
      TREXIMA tablet followed by IMITREX® (sumatriptan succinate) Injection 6mg administered using&#xD;
      the IMITREX STATdose System® compared with an IMITREX Tablet 100mg followed by an IMITREX&#xD;
      Tablet 100mg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2008</start_date>
  <completion_date type="Actual">June 14, 2008</completion_date>
  <primary_completion_date type="Actual">June 14, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) after the second dose and total exposure (measured by AUC(0-∞) calculated as pooled exposure from both the initial and second dose).</measure>
    <time_frame>ten weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events, blood pressure, pulse, ECGs and clinical laboratory tests.</measure>
    <time_frame>ten weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (4mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (6mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TREXIMA tablet followed by IMITREX® (sumatriptan succinate) Injection 6mg administered using the IMITREX STATdose System®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMITREX tablet (100mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TREXIMA™</intervention_name>
    <description>sumatriptan succinate / naproxen sodium tablet</description>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (4mg)</arm_group_label>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (6mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMITREX® (4mg)</intervention_name>
    <description>sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®</description>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (4mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMITREX® (6mg)</intervention_name>
    <description>sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®</description>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (6mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMITREX Tablet 100mg</intervention_name>
    <description>IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet</description>
    <arm_group_label>IMITREX tablet (100mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult males and females between 18 and 55 years of age, inclusive. Healthy&#xD;
             subjects are defined as individuals who are free from clinically significant illness&#xD;
             or disease as determined by their medical history, physical examination, laboratory&#xD;
             studies and other tests.&#xD;
&#xD;
          -  Female subjects of non-childbearing potential&#xD;
&#xD;
          -  Any subject taking oral contraceptives has been on a stable regimen for at least 2&#xD;
             months prior to screening.&#xD;
&#xD;
          -  BMI: 20-30 kg/m2, inclusive.&#xD;
&#xD;
          -  Subject is willing and able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who suffer from migraine attacks.&#xD;
&#xD;
          -  Subject has confirmed or suspected ischemic heart disease; angina pectoris, history of&#xD;
             myocardial infarction, documented silent ischemia, Prinzmetal's angina-coronary&#xD;
             vasospasm, signs, or symptoms consistent with any of the above.&#xD;
&#xD;
          -  Subject has evidence or history of ischemic abdominal syndromes, peripheral vascular&#xD;
             disease or Raynaud's syndrome.&#xD;
&#xD;
          -  Subject has cardiac arrhythmias requiring medication or a history of a clinically&#xD;
             significant electrocardiogram abnormality that, in the investigator's opinion,&#xD;
             contraindicates participation in this study.&#xD;
&#xD;
          -  Subject has a history of cerebrovascular pathology including stroke and/or transient&#xD;
             ischemic attacks.&#xD;
&#xD;
          -  Subject has a history of congenital heart disease.&#xD;
&#xD;
          -  Subject has hypertension at screening.&#xD;
&#xD;
          -  Subject, in the investigator's opinion, is likely to have unrecognized cardiovascular&#xD;
             or cerebrovascular disease.&#xD;
&#xD;
          -  Subject has a history of epilepsy or structural brain lesions which lower the&#xD;
             convulsive threshold or treated with an antiepileptic drug for seizure control within&#xD;
             5 years prior to screening.&#xD;
&#xD;
          -  History of impaired hepatic or renal function.&#xD;
&#xD;
          -  Subject is currently taking or has taken in the previous 4 weeks, herbal preparations&#xD;
             containing St. John's Wort.&#xD;
&#xD;
          -  Use of other prescription or non-prescription drugs, vitamins, herbal and dietary&#xD;
             supplements, within 7 days prior to the first dose of study medication.&#xD;
&#xD;
        Note: Excluded from this list are: acetaminophen at doses of less than or equal to 2 grams&#xD;
        per day and contraceptives.&#xD;
&#xD;
          -  Subject has a hypersensitivity, intolerance, or contraindication to the use of&#xD;
             sumatriptan or naproxen sodium or any of their components or any other 5-HT1 receptor&#xD;
             agonist.&#xD;
&#xD;
          -  Subject has a history of any gastrointestinal surgery that specifically indicates a&#xD;
             past history of bleeding, ulceration or perforation.&#xD;
&#xD;
          -  Subject has a history of gastric bypass or stapling surgery.&#xD;
&#xD;
          -  Subject has a history of GI ulceration in the past six months or gastrointestinal&#xD;
             bleeding in the past year.&#xD;
&#xD;
          -  Subject has a history of inflammatory bowel disease.&#xD;
&#xD;
          -  Treatment with an investigational drug within 30 preceding the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Positive serum beta-human chorionic gonadotropin test -females.&#xD;
&#xD;
          -  Pregnant, actively trying to become pregnant or breast-feeding.&#xD;
&#xD;
          -  Subjects with a history of drug or alcohol abuse.&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 7 drinks per week for females or 14&#xD;
             drinks per week for men within 6 months of screening.&#xD;
&#xD;
          -  Positive urine drug screen including alcohol at screening.&#xD;
&#xD;
          -  Donation of blood in excess of 500 mL within 56 days prior to first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Subjects who smoke more than 10 cigarettes per day.&#xD;
&#xD;
          -  History of sensitivity to heparin, heparin-induced thrombocytopenia or sensitivity to&#xD;
             any of the study medications or components thereof.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sumatriptan exposure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

